Incorvaia et al. showed that high baseline sPD-L1 correlated with longer PFS (median: 19 vs 9 months) in clear cell renal cell carcinoma patients treated with nivolumab [87], while Zhao et al. observed that high baseline sPD-L1 correlated with a better response to anti-PD-1 or anti-PD-L1 monotherapy in patients with a variety of cancers [88]. The gene discussed is PDCD1; the disease is cancer.